Fig. 4From: Expression of a recombinant FLT3 ligand and its emtansine conjugate as a therapeutic candidate against acute myeloid leukemia cells with FLT3 expressionImmunoblot analysis of the phosphorylation levels of FLT3 and AKT in MV-4-11 cells (a) and THP-1 cells (b) treated with rhFL (5Â nM) versus FL-DM1 (5Â nM). The total levels of FLT3 and AKT were used as controlsBack to article page